Role of the TFG N-terminus and coiled-coil domain in the transforming activity of the thyroid TRK-T3 oncogene
- PMID: 9488046
- DOI: 10.1038/sj.onc.1201596
Role of the TFG N-terminus and coiled-coil domain in the transforming activity of the thyroid TRK-T3 oncogene
Abstract
The thyroid TRK-T3 oncogene results from the fusion of the tyrosine kinase (TK) domain of NTRK1 (one of the receptors for the Nerve Growth Factor) on chromosome 1 to sequences of a novel gene, TFG, on chromosome 3. The 68 kDa TRK-T3 fusion oncoprotein displays a constitutive tyrosine kinase activity resulting in its capability to transform mouse NIH3T3 cells. The TFG portion of TRK-T3 contains a coiled-coil domain most likely responsible for the constitutive, ligand-independent activation of the receptor tyrosine kinase activity. We have previously shown that TRK-T3 oncoprotein forms, in vivo, complexes of three or four molecules. By mean of different experimental approaches, we show here that TRK-T3 activity depends on oligomers formation. In addition, the analysis of different TRK-T3 mutants indicates that the TFG coiled-coil domain and its N-terminal region are both required for the activation and the fully transforming activity of the TRK-T3 oncoprotein, although, most likely, they play a role in different steps of the transforming process. The deletion of the coiled-coil domain abrogates the oligomers formation leading to a constitutive activation; the deletion of the N-terminal region, although not affecting phosphorylation and complexes formation, abrogates transformation, thus suggesting a role in cellular localization and/or interaction with substrata.
Similar articles
-
Role of TFG sequences outside the coiled-coil domain in TRK-T3 oncogenic activation.Oncogene. 2003 Feb 13;22(6):807-18. doi: 10.1038/sj.onc.1206189. Oncogene. 2003. PMID: 12584559
-
The DNA rearrangement that generates the TRK-T3 oncogene involves a novel gene on chromosome 3 whose product has a potential coiled-coil domain.Mol Cell Biol. 1995 Nov;15(11):6118-27. doi: 10.1128/MCB.15.11.6118. Mol Cell Biol. 1995. PMID: 7565764 Free PMC article.
-
Oncogenic activation of the tyrosine kinase domain of the human trk proto-oncogene by fusion to a cell adhesion molecule.Oncogene. 1996 Oct 17;13(8):1755-63. Oncogene. 1996. PMID: 8895522
-
[Neurotrophins. I: Molecular features].Rev Med Univ Navarra. 1997 Jul-Sep;41(3):173-9. Rev Med Univ Navarra. 1997. PMID: 10420923 Review. Spanish.
-
Rearrangements of NTRK1 gene in papillary thyroid carcinoma.Mol Cell Endocrinol. 2010 May 28;321(1):44-9. doi: 10.1016/j.mce.2009.10.009. Epub 2009 Oct 31. Mol Cell Endocrinol. 2010. PMID: 19883730 Review.
Cited by
-
Deregulation of JAK2 signaling underlies primary cutaneous CD8+ aggressive epidermotropic cytotoxic T-cell lymphoma.Haematologica. 2022 Mar 1;107(3):702-714. doi: 10.3324/haematol.2020.274506. Haematologica. 2022. PMID: 33792220 Free PMC article.
-
TFG is required for autophagy flux and to prevent endoplasmic reticulum stress in CH12 B lymphoma cells.Autophagy. 2021 Sep;17(9):2238-2256. doi: 10.1080/15548627.2020.1821546. Epub 2020 Sep 22. Autophagy. 2021. PMID: 32910713 Free PMC article.
-
Biological activity of the thyroid TRK-T3 oncogene requires signalling through Shc.Br J Cancer. 2002 Sep 9;87(6):645-53. doi: 10.1038/sj.bjc.6600544. Br J Cancer. 2002. PMID: 12237775 Free PMC article.
-
Classification models for predicting the bioactivity of pan-TRK inhibitors and SAR analysis.Mol Divers. 2024 Aug;28(4):2077-2097. doi: 10.1007/s11030-023-10735-2. Epub 2023 Nov 1. Mol Divers. 2024. PMID: 37910346
-
Research Progress on Small Molecules Inhibitors Targeting TRK Kinases.Curr Med Chem. 2023;30(10):1175-1192. doi: 10.2174/0929867329666220801145639. Curr Med Chem. 2023. PMID: 35927900
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources